ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
April 07, 2020Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most
Pharma Sources Insight January 2025
